Loading...
•
Jun 30, 2023
Tvardi Therapeutics Q2 2023 Earnings Report
Cara Therapeutics reported second quarter 2023 financial results.
Key Takeaways
Cara Therapeutics reported Q2 2023 total revenue of $6.9 million, which includes collaborative revenue of $5.4 million from KORSUVA injection sales. Net loss for the quarter was $31.5 million, or $(0.58) per basic and diluted share. The company's cash, cash equivalents, and marketable securities totaled $101.7 million as of June 30, 2023.
Total revenue for Q2 2023 was $6.9 million, including $5.4 million in collaborative revenue from KORSUVA injection.
KORSUVA injection vial orders increased by 46% quarter-over-quarter, indicating accelerating demand.
Net loss for Q2 2023 was $31.5 million, or $(0.58) per basic and diluted share.
Cash, cash equivalents, and marketable securities totaled $101.7 million as of June 30, 2023.
Forward Guidance
The company expects its current unrestricted cash and cash equivalents and available-for-sale marketable securities, including collaborative revenue from its share of the profit from KORSUVA injection, will be sufficient to fund its currently anticipated operating plan for at least the next 12 months.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...